RESUMEN
ObjectiveTo observe the effect of Jiangzhi Tongluo soft capsule on the protein levels of silent mating-type information regulation 2 homolog 1 （SIRT1） and forkhead transcription factor FoxO3 and podocyte apoptosis in the renal tissue of rats with membranous nephropathy and to reveal the underlying molecular mechanisms for the treatment of MN. MethodSixty male SD rats were randomly assigned into 6 groups with 10 rats each. The six groups included a normal group， a model group， benazepril hydrochloride group， and Jiangzhi Tongluo soft capsule groups of low， medium and high doses （25， 50， 100 mg·kg-1， respectively）. The model rats were established by injection with cationized bovine serum albumin into the tail vein. After modeling， the rats were administrated with corresponding agents by gavage for 4 weeks. At the end of the 4th week， an electron microscope was used to observe the pathological changes in the kidney. Western blot was employed to detect the protein levels of SIRT1 and FoxO3 protein in rat kidney， and immunohistochemistry to detect the expression of B lymphocytoma-2 （Bcl-2）， Bcl-2-associated X protein （Bax）， Bcl-2-associated death promoter （Bad）， and podocyte split diaphragm proteins nephrin and podocin. ResultCompared with normal group， the expression of pro-apoptotic factors Bax， Bad， and FoxO3 in the kidney was up-regulated （P<0.05）， while that of anti-apoptotic factors Bcl-2， SIRT1， nephrin， and podocin was down-regulated （P<0.05） after modeling. Compared with the model group， the treatments down-regulated the expression of Bax， Bad， and FoxO3 （P<0.05） and up-regulated that of Bcl-2， SIRT1， nephrin， and podocin （P<0.05）. ConclusionJiangzhi Tongluo soft capsule may regulate the SIRT1/FoxO3 pathway to reduce podocyte apoptosis and maintain podocyte structure stability， thereby exerting the renal protection effect.
RESUMEN
Objective: To observe the effects of Jiangzhi Tongluo Soft Capsule on blood biochemical indexes and expression of Bcl-2 and Bad in membranous nephropathy (MN) rats, explore the renal protective effects and possible mechanism of Jiangzhi Tongluo Soft Capsule on MN rats. Methods: Total 60 SD rats were randomly selected, 10 for normal group, the other 50 for MN model establishment, then randomly divided into model group, Benazepril group, and Jiangzhi Tongluo Soft Capsule group (25, 50, and 100 mg/kg), each group was treated according to the corresponding dose. The 24 h urinary protein quantitative (UTP), serum total cholesterol (TC), triglyceride (TG), total protein (TP), albumin (ALB), blood urea nitrogen (BUN), and serum creatinine (Scr) in rats in the 4th weekend were tested; The renal pathological morphology changes were observed by electron microscope and immunofluorescence technique, and detecting the expression of Bcl-2, Bad by immunohistochemical and real-time PCR methods. Results: Compared with the model group, UTP, TC, and TG in the treatment groups were lower (P 0.05), and the effect was better than Jiangzhi Tongluo Soft Capsule 25 mg/kg group (P 0.05). Compared with the model group, the expression of Bcl-2 mRNA significantly raised (P 0.05), and the effect was better than that in Jiangzhi Tongluo Soft Capsule 25mg/kg group (P < 0.05). Conclusion: The renal protection of Jiangzhi Tongluo Soft Capsule on MN rats may be related to the function of raising the expression of Bcl-2, downgrading the expression of Bad, inhibiting the sertoli cell apoptosis, and repairing the damaged cells.